Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

V Subbiah, MI Hu, LJ Wirth, M Schuler… - The lancet Diabetes & …, 2021 - thelancet.com
Background Oncogenic alterations in RET represent important therapeutic targets in thyroid
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent …
被引用次数：278 相关文章

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

V Subbiah, MI Hu, LJ Wirth… - … lancet. Diabetes & …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Oncogenic alterations in RET represent important therapeutic targets in thyroid
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent …

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

V Subbiah, MI Hu, LJ Wirth, M Schuler… - The Lancet Diabetes & …, 2021 - Elsevier
Background Oncogenic alterations in RET represent important therapeutic targets in thyroid
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent …

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.

V Subbiah, MI Hu, LJ Wirth… - Lancet Diabetes …, 2021 - digitalcommons.providence.org
BACKGROUND: Oncogenic alterations in RET represent important therapeutic targets in
thyroid cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly …

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

V Subbiah, MI Hu, LJ Wirth… - The Lancet …, 2021 - mdanderson.elsevierpure.com
Background: Oncogenic alterations in RET represent important therapeutic targets in thyroid
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent …

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.

V Subbiah, MI Hu, LJ Wirth, M Schuler… - The lancet. Diabetes …, 2021 - europepmc.org
Background Oncogenic alterations in RET represent important therapeutic targets in thyroid
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent …

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

V Subbiah, MI Hu, LJ Wirth… - The Lancet …, 2021 - providence.elsevierpure.com
Background: Oncogenic alterations in RET represent important therapeutic targets in thyroid
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent …

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

V Subbiah, MI Hu, LJ Wirth, M Schuler… - The Lancet Diabetes …, 2021 - kclpure.kcl.ac.uk
Background: Oncogenic alterations in RET represent important therapeutic targets in thyroid
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent …

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

V Subbiah, M Hu, LJ Wirth, M Schuler… - … lancet. Diabetes & …, 2021 - scholarship.miami.edu
Background Oncogenic alterations in RET represent important therapeutic targets in thyroid
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent …

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

V Subbiah, MI Hu, LJ Wirth, M Schuler… - The Lancet Diabetes …, 2021 - profiles.wustl.edu
Background: Oncogenic alterations in RET represent important therapeutic targets in thyroid
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent …